Genetic diagnostics of hereditary breast and ovarian cancer (HBOC) has been performed in Slovakia in many different forms before the year 2000. Complex HBOC genetic analysis consists of many steps, including the initial genetic consultation, laboratory testing of genes associated with HBOC, interpretation and report of DNA analysis results, secondary explanatory genetic consultation and recommendation of clinical management for pathological mutation carriers. Many clinicians are participating on this workflow, such as clinical geneticists, laboratory diagnosticians as well as gynaecologists, oncologists or radio-diagnosticians. Currently, genetic testing is still technically and financially demanding and aimed only at selected families or patients who fulfil the defined clinical indication criteria. Positive result of DNA analysis, that is, detection of pathological mutation in genes associated with HBOC syndrome means that the risk of breast/ovarian cancer onset in mutation carriers is amplified. This predisposition markedly affects the clinical management and treatment of patient and other members of the family, thus creating the demand to establish widely accepted specific recommendations for genetic diagnostics of HBOC. In the past, the analysis of HBOC in Slovakia followed various technical approaches and indication criteria depending on the workflow of specific laboratory. The guidelines reported below adhere to the current trends in DNA analysis and clinical healthcare, define the criteria for diagnostic laboratories, conditions for genetic testing and determine indications for selection of HBOC families and further clinical management of mutation carriers.
INTRODUCTION
Breast cancer incidence is rising worldwide, and in many countries, it represents the most frequent malignity among women. The overall risk of breast cancer onset in general population is estimated at 12.5% and ovarian cancer at 4-5%. On the other hand, in Slovak women population, the average risk for breast cancer is reported at 8-10% and ovarian cancer at 2%. Approximately 5-10% of all breast/ovarian cancer (BOC) cases are associated with a hereditary pattern and thus marked as hereditary breast/ovarian cancer syndrome (HBOC). In the group of HBOC, mutations in BRCA1/2 genes represent the majority -about 80%; however, 20% of mutations occur in other low-penetrant genes (e.g. TP53, CHEK2, PALB2, CDH1, RAD51C, PTEN and others) (Apostolou et al., 2013) . Typical characteristics of the HBOC are the multiple occurrences of breast and/or ovarian cancer in family history, and the associated cancer types such as prostate, pancreatic, colon, melanoma, and endometrial cancer. Second important characteristic is low age at the onset of disease, mainly around 40-50 years of age (Miki et al., 1994) . The risk of disease onset before the age of 35-40 years in women carriers of BRCA1 mutation rises to 45-60% in breast and 20-60% in ovarian cancer cases, while in carriers of BRCA2 mutation, the risk is reported at 25-40% in breast and 10-20% in ovarian cancer cases. The risk of breast cancer onset in men carrying BRCA2 mutation is also increased to 6-10%, the prostate cancer risk increased to 20% and risk of pancreas cancer to 3% (Giordano, 2005 , Antoniou et al., 2003 . However, the risk of breast cancer diagnosis is modified by other factors, such as family history, age at disease onset, menarche history, usage of hormonal therapy, presence of benign lesions, deficiency of physical activity, obesity mainly in postmenopausal age and alcohol intake as well (Tea et al., 2013 , McPherson et al., 2000 . Cancer-associated genes are categorised according to the relative risk of disease onset into three groups: highpenetrant genes (BRCA1, BRCA2) with relative risk factor above 5, medium-penetrant genes (TP53, CDH1) with risk factor 1.5-5 and low-penetrant genes (PALB2, CHEK2) with risk factor reported at the level below 1.5 (Apostolou et al., 2013) . In total, mutations in more than 20 different genes are referred to be associated with HBOC. Mutations in highly penetrant genes might be responsible for 5-6% and mutations in medium-and low-penetrant genes for 4-5% of all BOC cases (Ishitobi et al., 2003) . The BRCA1 gene was first cloned in 1994 by Miki and coworkers (Miki et al., 1994) who have localised it to the chromosome 17 and established its association with BOC by linkage analysis in families with early-onset breast cancer. However, the existence of families with a strong history of breast cancer with no mutations in BRCA1 gene suggested the involvement of other genetic factors. In the same year, Wooster et al. (Wooster et al., 1994) identified BRCA2 gene on chromosome 13 and cloned it. BRCA1 gene consists of 22 coding exons (and 2 non-coding) and encodes 1836-amino acid protein with translation start in exon 2. This protein carries several functional domains: RING Finger at N-terminal end, nuclear localising domain in the centre and BRCT domain at the C terminus. The protein has important functions in cell cycle control, DNA repair, ubiquitination, apoptosis and so on (Bork et al., 1997) . The BRCA2 is larger than BRCA1, consists of 26 coding exons (and 1 non-coding) and encodes much larger protein of 3418 amino acids. The BRCA2 protein consists of only one functional domain -BRC, which serves as an interaction region for the DNA repair protein RAD51 (Bignell et al., 1997) . Predictive factors for the presence of mutations in BRCA1/2 genes are: high number of breast/ovarian cancer patients in the family, age at the onset of disease, Ashkenazi Jewish ancestry of the proband and characteristic pathological features of the tumour (e.g. triple negativity of hormone receptors). Incidence and spectrum of particular pathological mutations between populations varies, while in isolated populations (Island, Ashkenazi), the founder effect of one or small number of BRCA1/2 mutations may be observed. HBOC also belongs to the group of rare diseases, thus the relevance of reported guidelines correspond to the effort of Slovak healthcare professionals to assign the national plan for rare diseases into Slovak legislation (Cisarik, 2013) .
STANDARD WORKFLOW IN COMPLEX GENETIC TESTING OF HBOC IN SLOVAKIA
According to published data, if there is a suspicion of HBOC, the routine testing of BRCA1/2 and selected parts of CHEK2 should be recommended to the patient. In the case of a very strong family and personal cancer history, testing of associated genes, for example, TP53, CHEK2, PALB2, CDH1, MLH1, and MSH2 should be considered as well. The extension of molecular-genetic DNA analysis is limited by the frequency of pathological mutations in the population and also actual technical possibilities of the laboratory. Molecular-genetic DNA testing should be indicated by clinical geneticist (physician with specialisation in clinical genetics) based on the recommendations from physician specialist (gynaecologist, oncologist, etc.) and indication criteria reported below. Before the laboratory testing, the patient has to attend genetic counseling where the patient is informed about the clinical specifics of inherited disease, the principle of DNA analysis, its possibilities and limitations and also the analysis of family history (Larsson et al., 2007) . Furthermore, the patient has to sign a consent for blood collection, DNA isolation and analysis as well as storing the DNA for further analyses. Another genetic counseling session takes place after the laboratory analysis, mainly for explanation of the DNA testing results, their interpretation, and guidance for other family relatives to undergo the analysis in case the pathological mutation was found. In the case of mutation carriers, the clinical geneticist also recommends special intensive surveillance programme (also known as dispensary clinical management) to the patients and even healthy probands. The ambition should be to inform the patient and relatives personally, or by a private letter, clearly and with maximum effort to the patient's comfort and provide information in a timely manner.
INDICATION CRITERIA FOR DNA ANALYSIS OF BRCA1/2 GENES
To achieve maximum efficiency of DNA testing in HBOC patients and due to the high technical, time and financial demands of these tests, the BRCA1/2 mutations cannot be tested in all breast/ovarian cancer cases in Slovak population. Thus, only individuals who fulfil the clinical criteria and thus, are at higher risk of cancer participate in the DNA testing. These criteria are based on available literature and are influenced by Czech and German criteria. Considering the importance of the molecular genetic analysis of HBOC-associated genes, the costliness and time consumption of the testing and subsequent clinical management of mutation carriers, it is highly recommended to verify each identified mutation in two independently collected samples. This applies to both patients as well as healthy probands (Gulati et al., 2008 
CLINICAL INTERPRETATION OF GENETIC TESTING AND RESULTS
The DNA testing of the individual with suspected HBOC syndrome may reveal presence of the BRCA1/2 causal pathogenic mutation. In such a case: -Special surveillance programme (clinical dispensary management) is recommended to the patient -carrier of the predisposition; testing for family-specific mutation is offered to all relatives.
Relatives who do not carry the mutation do not have increased risk of BOC, this relieves them from the mental pressure connected with the possibility of cancer onset.
The DNA testing may reveal mutations with unclear clinical importance or there is no mutation detected in the individual: -Further genetic analysis for relatives is not advised.
-
The cancer risk factor may be calculated for the relatives based on the Claus model and genealogic data.
In the case of unfavourable family history (medium to high risk), the individuals are recommended for individual clinical management. The pathogenic mutation may not have been identified due to technical limitation or it may be localised in yet untested gene or region of the DNA.
CLINICAL MANAGEMENT OF HBOC MUTATION CARRIERS
Individuals with verified pathogenic mutation in mentioned genes should be included into special surveillance programmes that raise the probability of early cancer detection and, in turn, successful therapy. All schemes reported below are based on the published data and schemes used in other countries (Plevova et 
